A Phase 1, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Effects of MEDI-563, A Humanized Anti-Interleukin-5 Receptor Alpha Monoclonal Antibody, on Airway Eosinophils in Adults With Atopic Asthma.

Trial Profile

A Phase 1, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Effects of MEDI-563, A Humanized Anti-Interleukin-5 Receptor Alpha Monoclonal Antibody, on Airway Eosinophils in Adults With Atopic Asthma.

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Jan 2016

At a glance

  • Drugs Benralizumab (Primary) ; Benralizumab (Primary)
  • Indications Asthma
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors MedImmune
  • Most Recent Events

    • 08 Jan 2016 Pooled analysis of 2 trials including 14 patients from this study and other study (see CTP700038860) were published in the Respiratory Medicine.
    • 31 Jul 2012 Actual initiation date changed from May 2008 to Jan 2008, and additional lead investigator (Gossage D) added as reported by ClinicalTrials.gov.
    • 31 Jul 2012 Actual end date changed from Jul 2011 to Mar 2011, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top